Convergence between Wnt-β-catenin and EGFR signaling in cancer

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Hu, Tianhui ^a   Li, Cunxi ^b  

^a XIAMEN UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BETA CATENIN; CHEMOKINE RECEPTOR CXCR4; DISHEVELLED PROTEIN; DROSOPHILA PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FRIZZLED PROTEIN; NAKED CUTICLE HOMOLOG 2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BASOLATERAL MEMBRANE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CARCINOGENESIS; CELL FUNCTION; CELL POLARITY; CELL PROLIFERATION; COLORECTAL CANCER; DISEASE ACTIVITY; DOWN REGULATION; EMBRYO DEVELOPMENT; EPITHELIUM CELL; EXOCYTOSIS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; OVARY TUMOR; PRIMARY TUMOR; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STOMACH CANCER; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 77956471611     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-236     Document Type: Article

References (76)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767. 10.1016/0092-8674(90)90186-I, 2188735.
2. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235-237. 10.1038/359235a0, 1528264.
3. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002, 99:1521-1526. 10.1073/pnas.032678499, 122223, 11818567.
4. Gross ME, Zorbas MA, Danels YJ, Garcia R, Gallick GE, Olive M, Brattain MG, Boman BM, Yeoman LC. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991, 51:1452-1459.
5. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995, 1:19-31.
6. Staal FJ, Luis TC, Tiemessen MM. WNT signalling in the immune system: WNT is spreading its wings. Nat Rev Immunol 2008, 8:581-593. 10.1038/nri2360, 18617885.
7. Tao Q, Yokota C, Puck H, Kofron M, Birsoy B, Yan D, Asashima M, Wylie CC, Lin X, Heasman J. Maternal wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos. Cell 2005, 120:857-871. 10.1016/j.cell.2005.01.013, 15797385.
8. Gao C, Chen YG. Dishevelled: The hub of Wnt signaling. Cell Signal 22:717-727. 10.1016/j.cellsig.2009.11.021, 20006983.
9. Jessen JR. Noncanonical Wnt signaling in tumor progression and metastasis. Zebrafish 2009, 6:21-28. 10.1089/zeb.2008.0571, 19292672.
10. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007, 17:45-51. 10.1016/j.gde.2006.12.007, 17208432.
11. Karbova E, Davidson B, Metodiev K, Trope CG, Nesland JM. Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol 2002, 10:175-180. 10.1177/106689690201000302, 12232570.
12. Salahshor S, Woodgett JR. The links between axin and carcinogenesis. J Clin Pathol 2005, 58:225-236. 10.1136/jcp.2003.009506, 1770611, 15735151.
13. Duval A, Gayet J, Zhou XP, Iacopetta B, Thomas G, Hamelin R. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999, 59:4213-4215.
14. Guo J, Cagatay T, Zhou G, Chan CC, Blythe S, Suyama K, Zheng L, Pan K, Qian C, Hamelin R, et al. Mutations in the human naked cuticle homolog NKD1 found in colorectal cancer alter Wnt/Dvl/beta-catenin signaling. PLoS One 2009, 4:e7982. 10.1371/journal.pone.0007982, 2776356, 19956716.
15. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005, 24:7746-7755. 10.1038/sj.onc.1209038, 16299534.
16. Pukrop T, Binder C. The complex pathways of Wnt 5a in cancer progression. J Mol Med 2008, 86:259-266. 10.1007/s00109-007-0266-2, 17952396.
17. Huang CL, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H, Ueno M. Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. J Clin Oncol 2005, 23:8765-8773. 10.1200/JCO.2005.02.2871, 16314637.
18. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, Kikuchi A. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006, 66:10439-10448. 10.1158/0008-5472.CAN-06-2359, 17079465.
19. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002, 1:279-288. 10.1016/S1535-6108(02)00045-4, 12086864.
20. Dejmek J, Dejmek A, Safholm A, Sjolander A, Andersson T. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res 2005, 65:9142-9146. 10.1158/0008-5472.CAN-05-1710, 16230369.
21. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, et al. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009, 8:90. 10.1186/1476-4598-8-90, 2770486, 19849855.
22. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003, 284:2-13. 10.1016/S0014-4827(02)00105-2, 12648462.
23. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991, 47:87-98.
24. Di Fiore PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J, Aaronson SA. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51:1063-1070. 10.1016/0092-8674(87)90592-7, 3500791.
25. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182. 10.1126/science.2885917, 2885917.
26. Rosenthal A, Lindquist PB, Bringman TS, Goeddel DV, Derynck R. Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell 1986, 46:301-309. 10.1016/0092-8674(86)90747-6, 3459590.
27. Watanabe S, Lazar E, Sporn MB. Transformation of normal rat kidney (NRK) cells by an infectious retrovirus carrying a synthetic rat type alpha transforming growth factor gene. Proc Natl Acad Sci USA 1987, 84:1258-1262. 10.1073/pnas.84.5.1258, 304406, 3469667.
28. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 2003, 10:1-21. 10.1677/erc.0.0100001, 12653668.
29. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007, 7:169-181. 10.1038/nrc2088, 17318210.
30. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002, 38:1065-1071. 10.1016/S0959-8049(02)00004-7, 12008194.
31. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001, 8:83-96. 10.1677/erc.0.0080083, 11397666.
32. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792. 10.1056/NEJMoa044238, 15728811.
33. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075. 10.1073/pnas.0709662105, 2538882, 18227510.
34. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 2005, 352:2136. author reply 2136, 10.1056/NEJM200505193522019, 15901872.
35. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 2009, 34:641-651. 10.1016/j.molcel.2009.04.034, 2719887, 19560417.
36. Szuts D, Freeman M, Bienz M. Antagonism between EGFR and Wingless signalling in the larval cuticle of Drosophila. Development 1997, 124:3209-3219.
37. Freeman M, Bienz M. EGF receptor/Rolled MAP kinase signalling protects cells against activated Armadillo in the Drosophila eye. EMBO Rep 2001, 2:157-162. 10.1093/embo-reports/kve019, 1083815, 11258709.
38. Nagaraj R, Banerjee U. Regulation of Notch and Wingless signalling by phyllopod, a transcriptional target of the EGFR pathway. Embo J 2009, 28:337-346. 10.1038/emboj.2008.286, 2646148, 19153610.
39. Weber U, Pataki C, Mihaly J, Mlodzik M. Combinatorial signaling by the Frizzled/PCP and Egfr pathways during planar cell polarity establishment in the Drosophila eye. Dev Biol 2008, 316:110-123. 10.1016/j.ydbio.2008.01.016, 2579749, 18291359.
40. Yu H, Seah A, Herman MA, Ferguson EL, Horvitz HR, Sternberg PW. Wnt and EGF pathways act together to induce C. elegans male hook development. Dev Biol 2009, 327:419-432. 10.1016/j.ydbio.2008.12.023, 2695933, 19154732.
41. Kim SE, Choi KY. EGF receptor is involved in WNT3a-mediated proliferation and motility of NIH3T3 cells via ERK pathway activation. Cell Signal 2007, 19:1554-1564. 10.1016/j.cellsig.2007.02.003, 17374561.
42. Schroeder JA, Troyer KL, Lee DC. Cooperative induction of mammary tumorigenesis by TGFalpha and Wnts. Oncogene 2000, 19:3193-3199. 10.1038/sj.onc.1203652, 10918574.
43. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-293. 10.1038/nm0302-289, 11875501.
44. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510. 10.1126/science.1116221, 16293724.
45. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004, 279:43261-43272. 10.1074/jbc.M404276200, 15294912.
46. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 2002, 277:22692-22698. 10.1074/jbc.M201975200, 11950845.
47. Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clin Cancer Res 2007, 13:6087-6092. 10.1158/1078-0432.CCR-07-0591, 17947472.
48. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109. 10.1053/j.gastro.2006.08.011, 17030180.
49. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B, Birnbaum D, Pebusque MJ. Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Oncogene 1999, 18:1903-1910. 10.1038/sj.onc.1202739, 10086345.
50. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr R, Simon R, Sauter G, Leibiger H, et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol 2004, 25:641-649.
51. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007, 9:R63. 10.1186/bcr1769, 2242658, 17897439.
52. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002, 161:1087-1097. 1867237, 12213737.
53. Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007, 27:466-480. 10.1128/MCB.01539-06, 1800800, 17074804.
54. Musgrove EA. Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?. Breast Cancer Res 2004, 6:65-68. 10.1186/bcr737, 400647, 14979908.
55. Civenni G, Holbro T, Hynes NE. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Rep 2003, 4:166-171. 10.1038/sj.embor.embor735, 1315833, 12612606.
56. Tan X, Apte U, Micsenyi A, Kotsagrelos E, Luo JH, Ranganathan S, Monga DK, Bell A, Michalopoulos GK, Monga SP. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005, 129:285-302. 10.1053/j.gastro.2005.04.013, 1821080, 16012954.
57. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515. 10.1016/S1535-6108(03)00304-0, 14706341.
58. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 2009, 36:547-559. 10.1016/j.molcel.2009.09.034, 19941816.
59. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 2002, 277:30935-30941. 10.1074/jbc.M201919200, 12063252.
60. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, Sizemore N. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005, 24:1021-1031. 10.1038/sj.onc.1208296, 15592509.
61. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999, 402:884-888.
62. Gschwind A, Hart S, Fischer OM, Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. Embo J 2003, 22:2411-2421. 10.1093/emboj/cdg231, 155989, 12743035.
63. Hazan RB, Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998, 273:9078-9084. 10.1074/jbc.273.15.9078, 9535896.
64. Piedra J, Martinez D, Castano J, Miravet S, Dunach M, de Herreros AG. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J Biol Chem 2001, 276:20436-20443. 10.1074/jbc.M100194200, 11279024.
65. Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N, Machinami R, Hirohashi S. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996, 13:883-889.
66. Zeng W, Wharton KA, Mack JA, Wang K, Gadbaw M, Suyama K, Klein PS, Scott MP. naked cuticle encodes an inducible antagonist of Wnt signalling. Nature 2000, 403:789-795. 10.1038/35001615, 10693810.
67. Rousset R, Mack JA, Wharton KA, Axelrod JD, Cadigan KM, Fish MP, Nusse R, Scott MP. Naked cuticle targets dishevelled to antagonize Wnt signal transduction. Genes Dev 2001, 15:658-671. 10.1101/gad.869201, 312650, 11274052.
68. Yan D, Wallingford JB, Sun TQ, Nelson AM, Sakanaka C, Reinhard C, Harland RM, Fantl WJ, Williams LT. Cell autonomous regulation of multiple Dishevelled-dependent pathways by mammalian Nkd. Proc Natl Acad Sci USA 2001, 98:3802-3807. 10.1073/pnas.071041898, 31133, 11274398.
69. Van Raay TJ, Coffey RJ, Solnica-Krezel L. Zebrafish Naked1 and Naked2 antagonize both canonical and non-canonical Wnt signaling. Dev Biol 2007, 309:151-168. 10.1016/j.ydbio.2007.04.018, 2729589, 17689523.
70. Katoh M. Molecular cloning, gene structure, and expression analyses of NKD1 and NKD2. Int J Oncol 2001, 19:963-969.
71. Li C, Franklin JL, Graves-Deal R, Jerome WG, Cao Z, Coffey RJ. Myristoylated Naked2 escorts transforming growth factor alpha to the basolateral plasma membrane of polarized epithelial cells. Proc Natl Acad Sci USA 2004, 101:5571-5576. 10.1073/pnas.0401294101, 397424, 15064403.
72. Hu T, Krezel AM, Li C, Coffey RJ. Structural studies of human Naked2: a biologically active intrinsically unstructured protein. Biochem Biophys Res Commun 2006, 350:911-915. 10.1016/j.bbrc.2006.09.121, 1661664, 17045239.
73. Li C, Hao M, Cao Z, Ding W, Graves-Deal R, Hu J, Piston DW, Coffey RJ. Naked2 acts as a cargo recognition and targeting protein to ensure proper delivery and fusion of TGF-alpha containing exocytic vesicles at the lower lateral membrane of polarized MDCK cells. Mol Biol Cell 2007, 18:3081-3093. 10.1091/mbc.E07-02-0172, 1949375, 17553928.
74. Cao Z, Li C, Higginbotham JN, Franklin JL, Tabb DL, Graves-Deal R, Hill S, Cheek K, Jerome WG, Lapierre LA, et al. Use of fluorescence-activated vesicle sorting for isolation of Naked2-associated, basolaterally targeted exocytic vesicles for proteomics analysis. Mol Cell Proteomics 2008, 7:1651-1667. 10.1074/mcp.M700155-MCP200, 2528074, 18504258.
75. Ding W, Li C, Hu T, Graves-Deal R, Fotia AB, Weissman AM, Coffey RJ. EGF receptor-independent action of TGF-alpha protects Naked2 from AO7-mediated ubiquitylation and proteasomal degradation. Proc Natl Acad Sci USA 2008, 105:13433-13438. 10.1073/pnas.0806298105, 2527346, 18757723.
76. Hu T, Li C, Cao Z, Van Raay TJ, Smith JG, Willert K, Solnica-Krezel L, Coffey RJ. Myristoylated Naked2 antagonizes Wnt-beta-catenin activity by degrading Dishevelled-1 at the plasma membrane. J Biol Chem 285:13561-13568. 10.1074/jbc.M109.075945, 20177058.